- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 1.1 MB)
Pembrolizumab – March 2022
Pembrolizumab (Renal cell carcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
9 September 2022